Global Information
회사소개 | 문의 | 비교리스트

RNA 기반 치료제 시장 : 유형(RNA 간섭, RNA 안티센스), 용도, 최종사용자별 - 세계 기회 분석 및 산업 예측(2021-2030년)

RNA Based Therapeutic Market by Disease Type (RNA interference and RNA antisense), Application and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059606
페이지 정보 영문 170 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,310,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,940,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,919,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,726,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



RNA 기반 치료제 시장 : 유형(RNA 간섭, RNA 안티센스), 용도, 최종사용자별 - 세계 기회 분석 및 산업 예측(2021-2030년) RNA Based Therapeutic Market by Disease Type (RNA interference and RNA antisense), Application and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030
발행일 : 2021년 12월 페이지 정보 : 영문 170 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 RNA 기반 치료제 시장 규모는 2021년 49억 3,838만 달러에서 예측 기간 중 17.6%의 CAGR로 추이하며, 2030년에는 251억 2,195만 달러 규모로 성장할 것으로 예측됩니다.

세계의 RNA 기반 치료제 시장은 암, 당뇨병, 인간면역결핍바이러스 감염증(HIV) 및 후천성면역결핍증후군(AIDS) , 결핵, 특정 심혈관계 질환 등 다양한 만성질환의 치료에 대한 가능성 및 건강한 라이프스타일을 촉진하기 위한 정부 구상의 증가로 인해 최근 큰 주목을 받고 있습니다. 특히 암 등의 분자진단에 대한 응용의 급증 및 합성 전달 캐리어 및 RNA에 대한 화학 수식의 개량도 향후 시장에 유익한 기회를 제공할 것으로 기대되고 있습니다. 또한 랩 및 연구 센터에서 게놈 해독에 대한 수요의 증가, 분자진단의 증가도 시장 성장의 기회를 제공할 것으로 예측됩니다.

세계의 RNA 기반 치료제 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모의 추이·예측, 유형·용도·최종사용자·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 개요

  • 시장의 정의·범위
  • 주요 조사 결과
  • 주요 기업의 포지셔닝
  • Porter의 산업 분석
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 시장 기회
    • 영향 분석
  • COVID-19 : 영향 분석

제4장 RNA 기반 치료제 시장 : 유형별

  • 개요
  • RNA 간섭(RNAi)
  • RNA 안티센스
    • 주요 시장 동향·성장요인·기회
    • 시장 규모·예측
    • 시장 분석 : 국가별

제5장 RNA 기반 치료제 시장 : 용도별

  • 개요
  • 유전성 질환
  • 자가면역질환
    • 시장 규모·예측
    • 시장 분석 : 국가별

제6장 RNA 기반 치료제 시장 : 최종사용자별

  • 개요
  • 연구기관
  • 병원·클리닉
    • 시장 규모·예측
    • 시장 분석 : 국가별

제7장 RNA 기반 치료제 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카·중동·아프리카
    • 주요 동향과 기회
    • 시장 규모·예측 : 유형별
    • 시장 규모·예측 : 용도별
    • 시장 규모·예측 : 최종사용자별
    • 시장 규모·예측 : 국가별

제8장 기업 개요

  • Alnylam Pharmaceuticals Inc
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals
  • Benitec Biopharma Inc.
  • Biogen
  • Gradalis, Inc.
  • Genzyme(Sanofi), Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Silence Therapeutics plc
KSA 22.03.08

LIST OF TABLES

  • TABLE 01.RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030($MILLION)
  • TABLE 02.RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI), BY REGION, 2020-2030($MILLION)
  • TABLE 03.RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE, BY REGION, 2020-2030($MILLION)
  • TABLE 04.RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030($MILLION)
  • TABLE 05.RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS, BY REGION, 2020-2030($MILLION)
  • TABLE 07.RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 08.RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030($MILLION)
  • TABLE 09.RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.RNA BASED THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 12.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 13.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 14.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 15.U.S. RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 16.U.S. RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 17.U.S. RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 18.CANADA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 19.CANADA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 20.CANADA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 21.MEXICO RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 22.MEXICO RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 23.MEXICO RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 24.EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 25.EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 26.EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 27.EUROPE RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 28.GERMANY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 29.GERMANY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 30.GERMANY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 31.FRANCE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 32.FRANCE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 33.FRANCE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 34.UK RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 35.UK RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 36.UK RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 37.ITALY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 38.ITALY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 39.ITALY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 40.SPAIN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 41.SPAIN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 42.SPAIN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 43.REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 44.REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 45.REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 46.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 47.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 48.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 49.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 50.JAPAN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 51.JAPAN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 52.JAPAN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 53.CHINA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 54.CHINA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 55.CHINA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 56.INDIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 57.INDIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 58.INDIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 59.AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 60.AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 61.AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 62.SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 63.SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 64.SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 65.REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 66.REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 67.REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 68.LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 69.LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 70.LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 71.LAMEA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 72.BRAZIL RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 73.BRAZIL RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 74.BRAZIL RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 75.SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 76.SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 77.SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 78.SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 79.SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 80.SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 81.REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 82.REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 83.REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 84.ALNYLAM: COMPANY SNAPSHOT
  • TABLE 85.ALNYLAM: OPERATING SEGMENTS
  • TABLE 86.ALNYLAM: PRODUCT PORTFOLIO
  • TABLE 87.ALNYLAM.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88.ARBUTUS: COMPANY SNAPSHOT
  • TABLE 89.ARBUTUS SEGMENTS
  • TABLE 90.ARBUTUS: PRODUCT PORTFOLIO
  • TABLE 91.ARROWHEAD: COMPANY SNAPSHOT
  • TABLE 92.ARROWHEAD: OPERATING SEGMENT
  • TABLE 93.ARROWHEAD: PRODUCT PORTFOLIO
  • TABLE 94.BENITEC: COMPANY SNAPSHOT
  • TABLE 95.BENITEC: OPERATING SEGMENTS
  • TABLE 96.BENITEC: PRODUCT PORTFOLIO
  • TABLE 97.BIOGEN: COMPANY SNAPSHOT
  • TABLE 98.BIOGEN: OPERATING SEGMENTS
  • TABLE 99.BIOGEN: PRODUCT PORTFOLIO
  • TABLE 100.GRADALIS: COMPANY SNAPSHOT
  • TABLE 101.GRADALIS: OPERATING SEGMENT
  • TABLE 102.GRADALIS: PRODUCT PORTFOLIO
  • TABLE 103.GENZYME: COMPANY SNAPSHOT
  • TABLE 104.GENZYME: OPERATING SEGMENTS
  • TABLE 105.SANOFI: PRODUCT PORTFOLIO
  • TABLE 106.SANOFI.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107.IONIS: COMPANY SNAPSHOT
  • TABLE 108.IONIS: OPERATING SEGMENTS
  • TABLE 109.IONIS: PRODUCT PORTFOLIO
  • TABLE 110.SAREPTA: COMPANY SNAPSHOT
  • TABLE 111.SAREPTA: OPERATING SEGMENT
  • TABLE 112.SAREPTA: PRODUCT PORTFOLIO
  • TABLE 113.SAREPTA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114.SILENCE: COMPANY SNAPSHOT
  • TABLE 115.SILENCE OPERATING SEGMENTS
  • TABLE 116.SILENCE: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.RNA BASED THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
  • FIGURE 04.TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
  • FIGURE 05.TOP INVESTMENT POCKETS WINNING STRATEGIES: BY COMPANY, 2018-2021 (%)
  • FIGURE 06.TOP PLAYER POSITIONING, 2020
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 08.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 11.MODERATR INTENSITY OF COMPETITIVE RIVALRY
  • FIGURE 12.IMPACT ANALYSES, RNA BASED THERAPEUTICS MARKET
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 19.ALNYLAM: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 20.ALNYLAM: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 21.ARBUTUS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 22.ARROWHEAD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 23.BENITEC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 24.BIOGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.BIOGEN: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 26.GENZYME: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.GENZYME: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 28.GENZYME: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 29.IONIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 31.SAREPTA: NET SALES, 2018-2020 ($MILLION)

The global RNA based therapeutics market generated $4,938.38 million in 2021, and is projected to reach $25,121.95 million by 2030, growing at a CAGR of 17.6% from 2021 to 2030.

RNA based therapeutics is a class of medications based on ribonucleic acid (RNA). RNA based therapeutics provides or modifies ribonucleic acid (RNA) to patients' cells. Now it has the potential to treat a wide variety of diseases, including cardiovascular disease, hemophilia, and cancer. Based on messenger RNA (mRNA), the main types of RNA therapeutics include antisense RNA (asRNA), RNA interference (RNAi), the agents of RNA interference (RNAi), catalytically active RNA molecules (ribozymes), and RNAs that bind proteins and other molecular ligands (aptamers). In addition, messenger RNA (mRNA) can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins, such as cystic fibrosis. Moreover, Prominent players in the global RNA based therapeutics market have opted various strategies such as type launches, approvals, and investments in R&D for advancement in RNA based therapeutics to strengthen their position in the market and sustain the competitive environment

.

The global RNA based therapeutics market has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, Human immunodeficiency virus infection and acquired immune deficiency syndrome (AIDS), Tuberculosis and certain cardiovascular conditions and rise in government initiatives to promote healthy lifestyle. Furthermore, rise in health awareness significantly contributes toward the growth of the market. However, factors such as dearth of skilled professionals and end-user budget constraints in developing countries are expected to restrain the market growth. Conversely, surge in number of applications in molecular diagnostics, particularly in cancer and improving synthetic delivery carriers and chemical modifications to RNA is expected to offer profitable opportunities for the market players in the near future. Furthermore, increase in demand for genomic sequencing in laboratories, and research centers, also increasing molecular diagnostics are expected to provide lucrative opportunities for the growth of the market in near future.

RNA based therapeutics is segmented into by type, by application, and by end user. Based on type, the market is segmented into RNA interference (RNAi) technologies and RNA antisense technologies. Based on application, the market is segmented into genetic disorders and auto immune disorders. Based on end user, the market is segmented into research institutes, and hospitals & clinics. Region wise, it is classified into the North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global RNA based therapeutic market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of RNA based therapeutic used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

  • RNA Interference (RNAi)
  • RNA antisense

By Application

  • Genetic disorders
  • Auto immune disorders

By End User

  • Research Institutes
  • Hospitals & Clinics
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Australia
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Alnylam Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Arbutus Biopharma Corporation
  • Genzyme (Sanofi)
  • Ionis Pharmaceuticals
  • Sarepta Therapeutics
  • Benitec Biopharma Inc
  • Arrowhead Pharmaceuticals
  • Biogen, Inc
  • Gradalis, Inc.

TABLE OF CONTENTS

CHAPTER 1- INTRODUTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Key Players
  • 1.5.Research methodology
    • 1.5.1.Secondary research
    • 1.5.2.Primary research
    • 1.5.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Top player positioning, 2020
  • 3.4.Porter's five forces analysis
    • 3.4.1.Bargaining power of suppliers
    • 3.4.2.Bargaining power of buyers
    • 3.4.3.Threat of new entrants
    • 3.4.4.Threat of substitutes
    • 3.4.5.Intensity of competitive rivalry
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Target Specificity and Selectivity of Treatment
      • 3.5.1.2.Initiatives From Government for Large-Scale Sequencing Projects
    • 3.5.2.Restraints
      • 3.5.2.1.Hurdles In Drug Delivery
      • 3.5.2.2.High Cost of Research and Threat of Failure
    • 3.5.3.Opportunities
      • 3.5.3.1.Early Commercialization of Pipeline Therapeutics Assists to Gain Competitive Advantage
      • 3.5.3.2.Multifactorial Disease Targeting
    • 3.5.4.Impact Analysis
  • 3.1.COVID-19 impact analysis on the RNA based therapeutics market

CHAPTER 4:RNA BASED THERAPEUTICS MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast, by Type
  • 4.2.RNA Interference (RNAi)
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.RNA Antisense
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country

CHAPTER 5:RNA BASED THERAPEUTICS MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast, by end user
  • 5.2.Genetic Disorders
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Auto immune disorders
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country

CHAPTER 6:RNA BASED THERAPEUTICS MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast, by end user
  • 6.2.Research Institutes
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Hospitals & Clinics
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country

CHAPTER 7:RNA BASED THERAPEUTICS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast, by region
  • 7.2.North America
    • 7.2.1.Key trends and growth opportunities
    • 7.2.2.Market size and forecast, by type
    • 7.2.3.Market size and forecast, by application
    • 7.2.4.Market size and forecast, by end user
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S.
      • 7.2.5.2.U.S. market size and forecast, by type
    • 7.2.6.Market size and forecast, by application
      • 7.2.6.1.U.S. market size and forecast, by end user
      • 7.2.6.2.Canada
      • 7.2.6.3.Canada market size and forecast, by type
      • 7.2.6.4.Canada market size and forecast, by application
      • 7.2.6.5.Canada market size and forecast, by end user
      • 7.2.6.6.Mexico
      • 7.2.6.7.Mexico market size and forecast, by type
      • 7.2.6.8.Mexico market size and forecast, by application
      • 7.2.6.9.Mexico market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key trends and growth opportunities
    • 7.3.2.Market size and forecast, by type
    • 7.3.3.Market size and forecast, by application
    • 7.3.4.Market size and forecast, by end user
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany.
      • 7.3.5.2.Germany market size and forecast, by type
      • 7.3.5.3.Germany market size and forecast, by application
      • 7.3.5.4.Germany market size and forecast, by end user
      • 7.3.5.5.France
      • 7.3.5.6.France market size and forecast, by type
      • 7.3.5.7.France market size and forecast, by application
      • 7.3.5.8.France market size and forecast, by end user
      • 7.3.5.9.UK
      • 7.3.5.10.UK market size and forecast, by type
      • 7.3.5.11.UK market size and forecast, by application
      • 7.3.5.12.UK market size and forecast, by end user
      • 7.3.5.13.Italy
      • 7.3.5.14.Italy market size and forecast, by type
      • 7.3.5.15.Italy market size and forecast, by application
      • 7.3.5.16.Italy market size and forecast, by end user
      • 7.3.5.17.Spain
      • 7.3.5.18.Spain market size and forecast, by type
      • 7.3.5.19.Spain market size and forecast, by application
      • 7.3.5.20.Spain market size and forecast, by end user
      • 7.3.5.21.Rest of Europe
      • 7.3.5.22.Rest of Europe market size and forecast, by type
      • 7.3.5.23.Rest of Europe market size and forecast, by application
      • 7.3.5.24.Rest of Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key trends and growth opportunities
    • 7.4.2.Market size and forecast, by type
    • 7.4.3.Market size and forecast, by application
    • 7.4.4.Market size and forecast, by end user
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan
      • 7.4.5.2.Japan market size and forecast, by type
      • 7.4.5.3.Japan market size and forecast, by application
      • 7.4.5.4.Japan market size and forecast, by end user
      • 7.4.5.5.China
      • 7.4.5.6.China market size and forecast, by type
      • 7.4.5.7.China market size and forecast, by application
      • 7.4.5.8.China market size and forecast, by end user
      • 7.4.5.9.India
      • 7.4.5.10.India market size and forecast, by type
      • 7.4.5.11.India market size and forecast, by application
      • 7.4.5.12.India market size and forecast, by end user
      • 7.4.5.13.Australia
      • 7.4.5.14.Australia market size and forecast, by type
      • 7.4.5.15.Australia market size and forecast, by application
      • 7.4.5.16.Australia market size and forecast, by end user
      • 7.4.5.17.South Korea
      • 7.4.5.18.South Korea market size and forecast, by type
      • 7.4.5.19.South Korea market size and forecast, by application
      • 7.4.5.20.South Korea market size and forecast, by end user
      • 7.4.5.21.Rest of Asia-Pacific
      • 7.4.5.22.Rest of Asia-Pacific market size and forecast, by type
      • 7.4.5.23.Rest of Asia-Pacific market size and forecast, by application
      • 7.4.5.24.Rest of Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key trends and opportunities
    • 7.5.2.Market size and forecast, by type
    • 7.5.3.Market size and forecast, by application
    • 7.5.4.Market size and forecast, by end user
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.2.Brazil market size and forecast, by type
      • 7.5.5.3.Brazil market size and forecast, by application
      • 7.5.5.4.Brazil market size and forecast, by end user
      • 7.5.5.5.Saudi Arabia
      • 7.5.5.6.Saudi Arabia market size and forecast, by type
      • 7.5.5.7.Saudi Arabia market size and forecast, by application
      • 7.5.5.8.Saudi Arabia market size and forecast, by end user
      • 7.5.5.9.South Africa
      • 7.5.5.10.South Africa market size and forecast, by type
      • 7.5.5.11.South Africa market size and forecast, by application
      • 7.5.5.12.South Africa market size and forecast, by end user
      • 7.5.5.13.Rest of LAMEA
      • 7.5.5.14.Rest of LAMEA market size and forecast, by type
      • 7.5.5.15.Rest of LAMEA market size and forecast, by application
      • 7.5.5.16.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.Alnylam Pharmaceuticals Inc
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.Arbutus Biopharma Corporation
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.Arrowhead Pharmaceuticals
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.Benitec Biopharma Inc.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.Biogen
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.Gradalis, Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segment
    • 8.6.4.Product portfolio
  • 8.7.Genzyme (Sanofi), Inc.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.Ionis Pharmaceuticals, Inc.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Sarepta Therapeutics
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.Silence Therapeutics plc
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
Back to Top
전화 문의
F A Q